Chronic pain can affect a person’s life in a myriad of ways. Asal Shirazi BEM, Founder of the Autoimmune Support & Awareness Foundation (ASA Foundation), talks us through some of the conditions associated with chronic pain and the advancements in pain management.
In a groundbreaking initiative to treat severe mental health conditions, a new research group in Cambridgeshire is conducting clinical trials to investigate the potential benefits of empathogens and psychedelics.
Adeem Azhar, Co-Founder and Chief Executive Officer at Core Prescribing Solutions, explains how the company’s innovative solutions are helping to tackle challenges within primary care and positively support the healthcare workforce.
Chronic pain is a complex condition with far-reaching consequences. This review explores the latest research on factors contributing to its development and the potential of early interventions to prevent its onset.
Lorna Rothery spoke to the Cancer Drug Development Forum’s Managing Director, Professor Jaap Verweij and Chairperson of the CDDF Board of Directors, Professor Ruth Plummer, about opportunities and challenges in oncology research and treatment.
In an aim towards battling the global threat of antimicrobial resistance (AMR), the University of Liverpool has been granted £1.3 million to lead the UK Government’s Fleming Fund Fellowship Programme.
A new daily pill that can effectively reduce the frequency of migraine attacks has been approved for use by the National Institute for Health and Care Excellence (NICE).
Researchers from Amsterdam UNC and Radboundumc have revealed a method to predict the effectiveness of antidepressants within a week of treatment
This advancement powered by...
Leading independent European antisense drug discovery company, Secarna, aims to bring novel and effective antisense therapeutic options to an increasing number of patients. CEO Alexander Gebauer tells us how.
Research conducted by the University of Surrey suggests that insulin icodec, a weekly basal injection, may be just as effective when treating type 1 diabetes compared to daily basal insulin treatments.
